Business Description
Canbridge Pharmaceuticals Inc
ISIN : KYG1821D1097
Description
Financial Strength
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.88 | |||||
Equity-to-Asset | -0.1 | |||||
Debt-to-Equity | -3.57 | |||||
Debt-to-EBITDA | -0.37 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -16.44 | |||||
Beneish M-Score | -3.57 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 98.3 | |||||
3-Year EBITDA Growth Rate | 27.4 | |||||
3-Year EPS without NRI Growth Rate | 25 | |||||
3-Year FCF Growth Rate | 1.2 | |||||
3-Year Book Growth Rate | 72.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 40.05 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 52.8 | |||||
9-Day RSI | 55.14 | |||||
14-Day RSI | 53.34 | |||||
6-1 Month Momentum % | -21.92 | |||||
12-1 Month Momentum % | -83.81 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.64 | |||||
Quick Ratio | 0.61 | |||||
Cash Ratio | 0.38 | |||||
Days Inventory | 125.72 | |||||
Days Sales Outstanding | 90.24 | |||||
Days Payable | 1559.72 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | 13.43 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 63.96 | |||||
Operating Margin % | -363.88 | |||||
Net Margin % | -388.85 | |||||
FCF Margin % | -305.98 | |||||
ROE % | -304.04 | |||||
ROA % | -72.1 | |||||
ROIC % | -128.24 | |||||
3-Year ROIIC % | -245.5 | |||||
ROC (Joel Greenblatt) % | -312.78 | |||||
ROCE % | -160.42 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.16 | |||||
EV-to-EBIT | -0.35 | |||||
EV-to-EBITDA | -0.36 | |||||
EV-to-Revenue | 1.32 | |||||
EV-to-FCF | -0.43 | |||||
Earnings Yield (Greenblatt) % | -285.71 | |||||
FCF Yield % | -265.01 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Canbridge Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 13.419 | ||
EPS (TTM) (€) | -0.123 | ||
Beta | 0 | ||
Volatility % | 93.34 | ||
14-Day RSI | 53.34 | ||
14-Day ATR (€) | 0.003846 | ||
20-Day SMA (€) | 0.031375 | ||
12-1 Month Momentum % | -83.81 | ||
52-Week Range (€) | 0.0235 - 0.175 | ||
Shares Outstanding (Mil) | 424.84 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Canbridge Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Canbridge Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Canbridge Pharmaceuticals Inc Frequently Asked Questions
What is Canbridge Pharmaceuticals Inc(FRA:MF1)'s stock price today?
When is next earnings date of Canbridge Pharmaceuticals Inc(FRA:MF1)?
Does Canbridge Pharmaceuticals Inc(FRA:MF1) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |